Search
BIOAGE Labs Inc
BIOAAdd to Watchlist
25.100USD
+0.840+3.46%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.11BMarket Cap
LossP/E TTM
More Details of BIOAGE Labs Inc Company
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
BIOAGE Labs Inc Info
Ticker SymbolBIOA
Company nameBIOAGE Labs Inc
IPO dateSep 26, 2024
CEOFortney (Kristen)
Number of employees62
Security typeOrdinary Share
Fiscal year-endSep 26
Address5885 Hollis Street
CityEMERYVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94608
Phone15108061445
Websitehttps://bioagelabs.com
Ticker SymbolBIOA
IPO dateSep 26, 2024
CEOFortney (Kristen)
Company Executives of BIOAGE Labs Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Kristen Fortney, Ph.D.
Dr. Kristen Fortney, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
976.95K
--
Dr. Dov A. Goldstein, M.D.
Dr. Dov A. Goldstein, M.D.
Chief Financial Officer
Chief Financial Officer
36.58K
+9.68%
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Independent Director
Independent Director
3.00K
--
Dr. Eric Morgen, M.D.
Dr. Eric Morgen, M.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
--
--
Dr. Paul D. Rubin, M.D.
Dr. Paul D. Rubin, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jean-Pierre (JP) Garnier, M.D., Ph.D.
Dr. Jean-Pierre (JP) Garnier, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Independent Director
Independent Director
--
--
Mr. Patrick G. Enright
Mr. Patrick G. Enright
Independent Director
Independent Director
--
--
Dr. James I. Healey, M.D., Ph.D.
Dr. James I. Healey, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Vijay Pande, Ph.D.
Dr. Vijay Pande, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Kristen Fortney, Ph.D.
Dr. Kristen Fortney, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
976.95K
--
Dr. Dov A. Goldstein, M.D.
Dr. Dov A. Goldstein, M.D.
Chief Financial Officer
Chief Financial Officer
36.58K
+9.68%
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Independent Director
Independent Director
3.00K
--
Dr. Eric Morgen, M.D.
Dr. Eric Morgen, M.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
--
--
Dr. Paul D. Rubin, M.D.
Dr. Paul D. Rubin, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jean-Pierre (JP) Garnier, M.D., Ph.D.
Dr. Jean-Pierre (JP) Garnier, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
FAQs
Who are the top five shareholders of BIOAGE Labs Inc?
The top five shareholders of BIOAGE Labs Inc are: Dr. Kristen Fortney, Ph.D.
How many institutions hold shares of BIOAGE Labs Inc (BIOA)?
As of 2026Q1, 243 institutions hold shares of BIOAGE Labs Inc, with a combined market value of approximately 28.69M, accounting for 65.54% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -3087692.00.